GSK Nabs Breakthrough Status on Blood Cancer Drug

Nov 03, 2017


GlaxoSmithKline got good news for its oncology research when its experimental drug for blood cancer received a “breakthrough” designation from the U.S. FDA.

The speedy regulatory review of GSK’s BCMA drug for multiple myeloma was also granted by the European Medicines Agency last month.

The drug’s promising Phase I clinical trial results will be discussed in detail on Dec. 11 at the annual meeting of the American Society of Hematology.

Read the Reuters coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments